文献速递肿瘤 PET/CT核素与放射性配体治疗

[68Ga]Ga-FAP-2286与[18F]FDG PET/CT在乳腺癌中的对比评估及[177Lu]Lu-FAP-2286治疗的初步体验

Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-01-19

另对4例患者给予单周期[177Lu]Lu-FAP-2286治疗并随访4个月。[68Ga]Ga-FAP-2286 PET/CT总病灶检出率显著高于[18F]FDG PET/CT,尤其在肝转移和骨转移方面。[177Lu]Lu-FAP-2286治疗未观察到III或IV级不良事件,4例中3例随访显示疾病稳定(SD)。

要点

  • [68Ga]Ga-FAP-2286 PET/CT总病灶检出率85.4%显著高于[18F]FDG PET/CT的70.5%。
  • 肝转移(94.7% vs. 68.9%)和骨转移(85.8% vs. 66.4%)检出率[68Ga]Ga-FAP-2286更优。
  • [177Lu]Lu-FAP-2286治疗4例中3例达SD,未见III或IV级不良事件。

核心结论

  • [68Ga]Ga-FAP-2286是乳腺癌有前景的显像剂,[177Lu]Lu-FAP-2286可能为晚期患者提供潜在治疗选择。

研究设计与样本

  • 比较两种显像剂的病灶阳性率、SUVmax及TBR,并按累及器官分层分析。
  • 4例患者接受单周期[177Lu]Lu-FAP-2286治疗并随访4个月评估疗效与安全性。

主要发现

  • [68Ga]Ga-FAP-2286 PET/CT总病灶检出率85.4%显著高于[18F]FDG PET/CT的70.5%(P < 0.001)。
  • 肝转移检出率94.7% vs. 68.9%(P < 0.001),骨转移85.8% vs. 66.4%(P < 0.001)。
  • 原发灶(100% vs. 100%)、区域淋巴结(85.4% vs. 81.4%,P = 0.388)及远处淋巴结(84.2% vs. 75.0%,P = 0.159)检出率无显著差异。
  • 骨转移灶[68Ga]Ga-FAP-2286的SUVmax(8.7 ± 3.9 vs. 6.7 ± 2.8,P = 0.002)和TBR(5.4 ± 2.2 vs. 3.8 ± 1.3,P < 0.001)显著高于[18F]FDG。
  • 原发灶、区域淋巴结、远处淋巴结、肺转移及肝转移的SUVmax或TBR在两显像剂间均无统计学显著差异(均P > 0.05)。

关键数值与推荐

  • [177Lu]Lu-FAP-2286注射后肿瘤摄取持续高至168小时。
  • 4例治疗患者肿瘤病灶平均吸收剂量分别为0.21 ± 0.09、0.27 ± 0.14、0.14 ± 0.05和1.02 ± 0.30 Gy/GBq。
  • 1例患者全部肿瘤病灶168小时总吸收剂量达54.23 Gy/GBq。
  • 未观察到III或IV级不良事件,4例中3例随访显示疾病稳定(SD)。

临床怎么用

  • 对疑似复发或转移性乳腺癌,尤其需评估肝、骨转移时,[68Ga]Ga-FAP-2286 PET/CT可能提高病灶检出。
  • [177Lu]Lu-FAP-2286单周期治疗在4例晚期患者中未出现III或IV级不良事件,3例达SD,提示需进一步研究。

局限性

  • 治疗评估仅纳入4例患者且为单周期、随访4个月,样本量小、随访时间短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Breast cancer is the most common malignancy among women and remains the leading cause of cancer-related death in this population. Radionuclide-based diagnostic and therapeutic approaches have emerged as effective and low-risk strategies for management of breast cancer. This study aimed to evaluate the diagnostic performance of [68Ga]Ga-FAP-2286 PET/CT compared with [18F]FDG PET/CT, and to provide a preliminary assessment of the clinical potential of [¹⁷⁷Lu]Lu-FAP-2286 radionuclide therapy in patients with advanced breast cancer. METHODS: A total of twenty patients with clinically suspected recurrent or metastatic breast cancer were prospectively enrolled. All participants underwent both [18F]FDG PET/CT and [68Ga]Ga-FAP-2286 PET/CT imaging within one week. The positivity rate of lesions, maximum standardized uptake value (SUVmax), and tumor-to-background ratio (TBR) were compared between the two imaging modalities across different involved organs. In addition, four patients received a single cycle of [¹⁷⁷Lu]Lu-FAP-2286 radionuclide therapy, and were followed for 4 months to assess therapeutic response and safety. RESULTS: The total number of lesions detected by [68Ga]Ga-FAP-2286 PET/CT was significantly higher than that detected by [18F]FDG PET/CT (85.4% vs. 70.5%, P < 0.001). This superiority was particularly evident for hepatic metastases (94.7% vs. 68.9%, P < 0.001) and bone metastases (85.8% vs. 66.4%, P < 0.001). In contrast, both modalities demonstrated comparable sensitivity in identifying primary breast tumors (100% vs. 100%), regional lymph node metastases (85.4% vs. 81.4%, P = 0.388), and distant lymph node metastases (84.2% vs. 75.0%, P = 0.159). With respect to semiquantitative parameters, [68Ga]Ga-FAP-2286 PET/CT demonstrated significantly higher uptake in bone metastases than [18F]FDG PET/CT (SUVmax: 8.7 ± 3.9 vs. 6.7 ± 2.8, P = 0.002; TBR: 5.4 ± 2.2 vs. 3.8 ± 1.3, P < 0.001). However, for primary tumors, regional lymph nodes, distant lymph nodes, pulmonary metastases, and hepatic metastases, no statistically significant differences in SUVmax or TBR values were observed between the two tracers (all P > 0.05). [177Lu]Lu-FAP-2286 demonstrated sustained high tumor uptake up to 168 h post-injection. In the four treated patients, the mean absorbed doses to tumor lesions were 0.21 ± 0.09, 0.27 ± 0.14, 0.14 ± 0.05, and 1.02 ± 0.30 Gy/GBq, respectively. Notably, in one patient, the total absorbed dose for all tumor lesions reached 54.23 Gy/GBq at 168 h. No grade III or IV adverse events were observed, and three of four patients exhibited stable disease (SD) on follow-up. CONCLUSION: [68Ga]Ga-FAP-2286 appears to be a promising imaging agent for breast cancer, while [177Lu]Lu-FAP-2286 may represent a potential therapeutic option for patients with advanced disease.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Liu W, Zhang N, Zheng W, et al. Comparative evaluation of [68Ga]Ga-FAP-2286 and [18F]FDG PET/CT in breast cancer and initial experience with [177Lu]Lu-FAP-2286 therapy. Eur J Nucl Med Mol Imaging. 2026. PMID: 41553532. doi:10.1007/s00259-026-07766-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。